Study guide

5.2 Antimetabolites & Folate Antagonists

BCOP Board Certified Oncology Pharmacist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & BCOP Exam Foundations

1.1 BCOP Exam Specifications, Passing Standard & Eligibility 1.2 The Clinical Oncology Pharmacist Scope of Practice & Core Competencies 1.3 Study Guide Methodology & Active Learning Strategy

2 Chapter 2: Cancer Biology & Pathophysiology

2.1 Hallmarks of Cancer, Multi-Step Carcinogenesis & Tumor Microenvironment 2.2 Cell Cycle Checkpoints, Apoptotic Pathways & DNA Damage Repair Mechanics 2.3 Tumor Immunology, Antigen Presentation & Mechanisms of Immune Evasion

3 Chapter 3: Genomic Biomarkers & Molecular Targets

3.1 Somatic vs Germline Mutations, NGS Profiling & Variant Classification 3.2 Actionable Oncogenic Driver Mutations & Targeted Kinase Inhibitors 3.3 Pharmacogenomics in Oncology: DPYD, TPMT, NUDT15, UGT1A1 & CYP2D6

4 Chapter 4: Diagnostics, Staging & Clinical Assessment

4.1 Circulating Tumor Markers, Flow Cytometry & Diagnostic Modalities 4.2 TNM Staging Systems, Histopathologic Grading & Hematologic Prognostic Indices 4.3 Performance Status Scales & Organ Function Assessment 4.4 Cancer Screening, Early Detection & Prevention

5 Chapter 5: Cytotoxic Chemotherapy Pharmacology & Regimens

5.1 Alkylating Agents & Platinum Analogs 5.2 Antimetabolites & Folate Antagonists 5.3 Topoisomerase Inhibitors, Anthracyclines & Cardiotoxicity Mitigation 5.4 Antimicrotubule Agents: Taxanes, Vinca Alkaloids & Halichondrins

6 Chapter 6: Targeted Small-Molecule Therapies

6.1 Small-Molecule Tyrosine Kinase Inhibitors in Solid Tumors 6.2 Hematologic Small-Molecule Kinase Inhibitors 6.3 Pathway-Specific Inhibitors: PARP, CDK4/6, BCL-2 & PI3K/AKT/mTOR Pathways

7 Chapter 7: Immunotherapy, Biologics & Cellular Therapy

7.1 Immune Checkpoint Inhibitors & irAE Management 7.2 Naked Monoclonal Antibodies, Antibody-Drug Conjugates & Bispecific T-Cell Engagers 7.3 Chimeric Antigen Receptor (CAR) T-Cell Therapies & Cellular Logistics

8 Chapter 8: Breast & Gynecologic Malignancies

8.1 Early-Stage & Locoregional Breast Cancer 8.2 Advanced & Metastatic Breast Cancer Targeted Strategies 8.3 Epithelial Ovarian, Endometrial & Cervical Malignancies

9 Chapter 9: Thoracic & Skin Malignancies

9.1 Early & Locally Advanced NSCLC & Small Cell Lung Cancer 9.2 Metastatic Non-Small Cell Lung Cancer (Driver-Positive and Driver-Negative) 9.3 Cutaneous Melanoma & Non-Melanoma Skin Cancers

10 Chapter 10: Gastrointestinal & Genitourinary Malignancies

10.1 Colorectal Cancer: Staging, Adjuvant Therapy, and Biomarker-Driven Metastatic Therapeutics 10.2 Esophagogastric, Pancreatic, and Hepatobiliary Malignancies 10.3 Genitourinary Malignancies: Prostate, Renal Cell, and Urothelial Carcinomas

11 Chapter 11: Hematologic Malignancies: Leukemias & Myeloma

11.1 Acute Myeloid & Acute Lymphoblastic Leukemias 11.2 Chronic Leukemias & Myeloproliferative Neoplasms 11.3 Multiple Myeloma & Plasma Cell Dyscrasias 11.4 Non-Malignant Hematologic Disorders: ITP, Aplastic Anemia, Sickle Cell Disease & TTP

12 Chapter 12: Lymphomas & Stem Cell Transplantation

12.1 Classical Hodgkin Lymphoma: Staging, Frontline Regimens & Relapsed/Refractory Strategies 12.2 Non-Hodgkin Lymphomas: Aggressive, Indolent, Mantle Cell & T-Cell Subtypes 12.3 Hematopoietic Stem Cell Transplantation, Complications & Graft-versus-Host Disease

13 Chapter 13: Supportive Care & Toxicity Management

13.1 Chemotherapy-Induced Nausea and Vomiting (CINV) Prophylaxis & Rescue 13.2 Myelosuppression, Febrile Neutropenia & Growth Factor Stewardship 13.3 Oncologic Emergencies: TLS, Hypercalcemia, Spinal Cord Compression & SVCS 13.4 Chemotherapy Extravasation, Organ Protectants & Antidotes

14 Chapter 14: Hazardous Drug Handling & Compounding Safety

14.1 USP <800> & NIOSH Hazardous Drug Standards 14.2 Engineering Controls, Personal Protective Equipment & Closed System Transfer Devices 14.3 Safe Handling, Surface Decontamination & Accidental Spill Response

15 Chapter 15: Chemotherapy Safety, Dosing & Order Verification

15.1 Regimen Standardization, Dose Calculation Formulas & Organ Adjustments 15.2 Independent Double-Check, Verification Checkpoints & Toxicity Gating 15.3 Oral Chemotherapy Management, Adherence & Specialty Pharmacy Coordination

16 Chapter 16: Clinical Trials, Biostatistics & Evidence Evaluation

16.1 Oncology Clinical Trial Designs, Endpoints & Statistical Power 16.2 Biostatistical Concepts: Hazard Ratios, Survival Analysis & Precision Metrics 16.3 Evidence Synthesis, Guideline Hierarchy & Critical Literature Appraisal

17 Chapter 17: Health Systems, Regulatory Compliance & Patient Education

17.1 Oncology Formulary Management, Biosimilars & Value Frameworks 17.2 Regulatory Mandates, REMS Programs & Investigational Drug Services 17.3 Patient & Caregiver Counseling, Survivorship Care & Palliative Ethics 17.4 Complementary, Alternative & Integrative Therapies in Oncology

5.2 Antimetabolites & Folate Antagonists

Key Takeaways Explain This Topic AI

Antimetabolites are S-phase specific cytotoxic antineoplastics that structurally resemble endogenous folate, purines, or pyrimidines, disrupting DNA/RNA synthesis through enzymatic inhibition (DHFR, TS, ribonucleotide reductase, DNA polymerase) or false nucleotide incorporation.

High-Dose Methotrexate (HDMTX >=500-1,000 mg/m2) requires rigorous supportive care: urine alkalinization (pH >=7.0) to prevent crystalline nephropathy, vigorous hydration (>=100 mL/hr), drainage of third-space fluid collections, avoidance of interacting drugs (NSAIDs, PPIs, penicillins, Bactrim), and quantitative Leucovorin rescue guided by serial MTX level nomograms.

Glucarpidase (recombinant carboxypeptidase G2) is a rescue antidote indicated for toxic methotrexate concentrations (>1 umol/L) in patients with delayed clearance due to renal impairment; it cleaves MTX into DAMPA and glutamate (note: leucovorin must not be given within 2 hours before/after glucarpidase).

Dihydropyrimidine Dehydrogenase (DPD, encoded by DPYD) catabolizes >80% of 5-FU; patients harboring DPYD deficient alleles (*2A, *13, c.2846A>T, HapB3) face life-threatening toxicity, requiring CPIC-directed 50% dose reductions or complete avoidance; Uridine Triacetate (Vistogard) is the specific antidote for fluoropyrimidine overdose/early severe toxicity administered within 96 hours.

6-Mercaptopurine (6-MP) is metabolized by TPMT, NUDT15, and Xanthine Oxidase (XO); co-administration of 6-MP with the XO inhibitors allopurinol or febuxostat requires a mandatory 67-75% dose reduction of 6-MP to avoid fatal myelosuppression (6-Thioguanine does not require dose reduction with allopurinol).

Last updated: August 2026

5.2 Antimetabolites & Folate Antagonists

Antimetabolites represent one of the oldest and most versatile classes of antineoplastic agents. By mimicking physiological purines, pyrimidines, and folate cofactors, these agents disrupt nucleic acid biosynthesis, halt replication forks, and trigger programed cell death. Because their cytotoxicity is exquisitely dependent on active DNA replication, antimetabolites are S-phase specific cell-cycle antineoplastics. Consequently, their therapeutic efficacy and toxicity profiles are highly sensitive to schedule and duration of exposure rather than peak concentrations alone.

1. Folate Antagonists: Methotrexate & Pemetrexed

Folate antagonists interfere with intracellular one-carbon transfer reactions essential for de novo synthesis of purine nucleotides (adenine and guanine) and thymidylate ( d T M P dTMP d TMP ). +-----------------------------------------------------------------------------+

  • | FOLATE METABOLIC PATHWAY & ANTIFOLATE TARGETS |
  • | |
  • | Dietary Folate / Dihydrofolate (DHF) |
  • | | |
  • | | <--- METHOTREXATE (Potent Competitive Inhibitor) |
  • | v PEMETREXED (Secondary Target) |
  • | [Dihydrofolate Reductase (DHFR)] |
  • | | |
  • | v |
  • | Tetrahydrofolate (THF) <========== [LEUCOVORIN / FOLINIC ACID] |
  • | | (Bypasses DHFR Inhibition) |
  • | v |
  • | 5,10-Methylene-THF |
  • | | |
  • | +------------------------+ |
  • | | | |
  • | <--- PEMETREXED | | <--- 5-FU (FdUMP + THF Ternary|
  • | (Primary) v v Complex Inhibits TS) |
  • | [Thymidylate Synthase] [GAR / AICAR Transformylases] |
  • | | | |
  • | v v |
  • | dTMP (Thymidine) Purines (Adenine, Guanine) |
  • | | | |
  • | +----------->+<----------+ |
  • | | |
  • | v |
  • | [DNA / RNA Biosynthesis] |
  • +-----------------------------------------------------------------------------+
  • A. Methotrexate (MTX) & High-Dose MTX (HDMTX) Protocols

Mechanism: Polyglutamated intracellularly; competitively inhibits Dihydrofolate Reductase (DHFR) ( K i < 1 pM K_i < 1\text{ pM} K i ​ < 1 pM ), depleting intracellular N 5 , N 10 N^5,N^{10} N 5 , N 10 -methylene-THF and halting both thymidylate and de novo purine synthesis.

HDMTX Definitions: Doses ≥ 500 mg/m 2 \ge 500\text{ mg/m}^2 ≥ 500 mg/m 2 up to 12 , 000 mg/m 2 12,000\text{ mg/m}^2 12 , 000 mg/m 2 (used in Osteosarcoma, Primary CNS Lymphoma, ALL, High-Grade B-cell Lymphomas). HDMTX passive diffusion overcomes cellular transport resistance but requires strict rescue to prevent fatal host toxicity.

Mandatory HDMTX Supportive Care Requirements:

Urine Alkalinization & Hydration:

Mechanism: Methotrexate and its primary hepatic metabolite 7-hydroxy-methotrexate (7-OH-MTX) have very poor water solubility in acidic environments (isoelectric point pH ~4.8–5.5). In acidic tubular urine, they precipitate into insoluble crystals, causing intratubular obstruction, direct tubular necrosis, and acute renal failure.

Goal: Pre-hydrate with IV fluids containing Sodium Bicarbonate ( 40 – 50 mEq/L 40\text{--}50\text{ mEq/L} 40 – 50 mEq/L ) at 150 – 200 mL/hr 150\text{--}200\text{ mL/hr} 150 – 200 mL/hr to ensure urine pH ≥ 7.0 \ge 7.0 ≥ 7.0 and urine output ≥ 100 mL/hr \ge 100\text{ mL/hr} ≥ 100 mL/hr prior to starting MTX and maintained continuously until serum MTX < 0.05 – 0.1 μ mol/L < 0.05\text{--}0.1\;\mu\text{mol/L} < 0.05 – 0.1 μ mol/L .

Third-Space Fluid Drainage:

Methotrexate slowly distributes into pathological third-space collections (pleural effusions, ascites). As systemic MTX levels fall, the drug slowly diffuses back into the intravascular compartment, creating a persistent, low-concentration plateau that bypasses renal clearance and causes lethal myelosuppression and mucositis. All significant pleural effusions and ascites must be drained prior to HDMTX.

Drug-Drug Interactions (Contraindicated / Hold):

NSAIDs & Salicylates: Inhibit renal prostaglandin-mediated perfusion and compete for organic anion transporters ( OAT1/OAT3 ), reducing MTX clearance by up to 50%.

Proton Pump Inhibitors (PPIs - Omeprazole, Esomeprazole): Inhibit the BCRP (breast cancer resistance protein) and OAT transporter-mediated renal elimination of MTX. Switch to H2RAs (famotidine) or hold PPIs 48–72 hours prior.

Penicillins, Cephalosporins, Probenecid: Compete directly for OAT3 tubular secretion.

Trimethoprim-Sulfamethoxazole (Bactrim): Additive DHFR inhibition + protein displacement; hold on HDMTX days.

Leucovorin (Folinic Acid / 5-formyl-THF) Rescue:

Leucovorin is a reduced folate cofactor that does not require DHFR for activation. It directly replenishes the intracellular reduced folate pool, rescuing normal dividing host tissues (bone marrow, gastrointestinal mucosa) from MTX toxicity.

Timing: Typically initiated 24 hours following the start of MTX infusion (starting too early abrogates antineoplastic efficacy; starting > 40 – 48 hours >40\text{--}48\text{ hours} > 40 – 48 hours late leads to irreversible mucosal and marrow destruction).

Dosing is dynamically adjusted using institutional MTX Elimination Nomograms (e.g., standard dose: 15 mg PO/IV q6h 15\text{ mg PO/IV q6h} 15 mg PO/IV q6h ; escalated to 50 – 150 mg/m 2 IV q3h 50\text{--}150\text{ mg/m}^2\text{ IV q3h} 50 – 150 mg/m 2 IV q3h if 24h, 48h, or 72h levels exceed safety thresholds). +-----------------------------------------------------------------------------+

  • | HDMTX LEUCOVORIN RESCUE NOMOGRAM ALGORITHM |
  • | |
  • | TIME POST-START NORMAL EXPECTED MTX LEVEL ACTION / LEUCOVORIN DOSE |
  • | ----------------------------------------------------------------------- |
  • | 24 Hours < 5 - 10 umol/L Standard Rescue: 15 mg q6h |
  • | 48 Hours < 1.0 umol/L Continue 15 mg q6h |
  • | 72 Hours < 0.1 - 0.2 umol/L Continue until <0.05-0.1 uM |
  • | |
  • | IF DELAYED ELIMINATION OCCURS: |
  • | 48h MTX >= 5 umol/L OR 72h MTX >= 1 umol/L: |
  • | -> Increase Leucovorin to 100-150 mg/m2 IV q3-6h |
  • | -> Intensify hydration + NaHCO3 (maintain urine pH >= 7.5) |
  • | -> If Renal Failure + MTX > 1-2 umol/L: Administer GLUCARPIDASE |
  • +-----------------------------------------------------------------------------+

Glucarpidase (Voraxaze - Recombinant Carboxypeptidase G2):

Indication: Indicated for the treatment of toxic plasma methotrexate concentrations ( > 1 μ mol/L >1\;\mu\text{mol/L} > 1 μ mol/L ) in patients with delayed MTX clearance due to acute impaired renal function.

Mechanism: Bacterial enzyme that rapidly hydrolyzes extracellular methotrexate into inactive metabolites: 4-deoxy-4-amino- N 10 N^{10} N 10 -methylpteroic acid ( DAMPA ) and glutamate, providing an alternate non-renal clearance route.

Dosing: 50 Units/kg 50\text{ Units/kg} 50 Units/kg as a single IV injection over 5 minutes.

Critical Interaction Rule: Do NOT administer Leucovorin within 2 hours before or after Glucarpidase. Glucarpidase hydrolyzes leucovorin as well, rendering both ineffective. Continue leucovorin ≥ 2 hours \ge 2\text{ hours} ≥ 2 hours after glucarpidase.

Laboratory Measurement Pearl: DAMPA cross-reacts with standard clinical immunoassays (CEDIA/FPIA) for MTX, producing falsely elevated MTX readings for 48 hours post-glucarpidase. Only chromatographic methods (LC-MS/MS) accurately measure MTX post-glucarpidase. Continue leucovorin based on pre-glucarpidase levels or institutional nomograms for 48 hours.

B. Pemetrexed (Alimta): Multi-Targeted Antifolate

Mechanism: Inhibits Thymidylate Synthase (TS), DHFR, and glycinamide ribonucleotide formyltransferase (GARFT). Indicated for non-squamous Non-Small Cell Lung Cancer (NSCLC) and Malignant Pleural Mesothelioma.

Mandatory Premedications & Safety Rules:

Folic Acid: 400 – 1 , 000 μ g PO daily 400\text{--}1,000\;\mu\text{g PO daily} 400 – 1 , 000 μ g PO daily starting ≥ 7 days \ge 7\text{ days} ≥ 7 days prior to cycle 1, continuing daily throughout therapy, and for 21 days after the last dose. Prevents life-threatening myelosuppression and severe mucositis/diarrhea.

Vitamin B12: 1 , 000 μ g IM 1,000\;\mu\text{g IM} 1 , 000 μ g IM starting 1 week prior to cycle 1 and repeated every 9 weeks (every 3 cycles).

Dexamethasone: 4 mg PO BID 4\text{ mg PO BID} 4 mg PO BID on days − 1 , 0 , + 1 -1, 0, +1 − 1 , 0 , + 1 (day before, day of, day after pemetrexed) to prevent severe cutaneous erythematous rash.

Renal Cutoff & NSAID Interactions: Contraindicated if CrCl < 45 mL/min \text{CrCl} < 45\text{ mL/min} CrCl < 45 mL/min . Hold short half-life NSAIDs (ibuprofen, ketorolac) 2 days before and 2 days after ( 5 days 5\text{ days} 5 days for long half-life NSAIDs like piroxicam/nabumetone) in patients with mild-to-moderate renal impairment ( CrCl 45 – 79 mL/min \text{CrCl } 45\text{--}79\text{ mL/min} CrCl 45 – 79 mL/min ).

2. Pyrimidine Analogs: Fluoropyrimidines & Cytarabine +-----------------------------------------------------------------------------+

  • | FLUOROPYRIMIDINE BIOACTIVATION & DPYD PATHWAY |
  • | |
  • | Oral CAPECITABINE (Prodrug) |
  • | | |
  • | | (Hepatic Carboxylesterase - CES1/CES2) |
  • | v |
  • | 5'-Deoxy-5-fluorocytidine (5'-DFCR) |
  • | | |
  • | | (Cytidine Deaminase - CDA in Liver/Tumor) |
  • | v |
  • | 5'-Deoxy-5-fluorouridine (5'-DFUR) |
  • | | |
  • | | (Thymidine Phosphorylase - TP, High in Tumors) |
  • | v |
  • | +---------------------------------------+ |
  • | | 5-FLUOROURACIL (5-FU) | |
  • | +---------------------------------------+ |
  • | | | |
  • | | Catabolism (>80%) | Anabolic Bioactivation (<20%) |
  • | v v |
  • | [DPYD / DPD Enzyme] +-------------------+ |
  • | (Inactivated to DHFU) | Active Metabolites| |
  • | +-------------------+ |
  • | *DEFICIENCY (*2A, *13, c.2846): | |
  • | Profound 5-FU Accumulation +---> FdUMP (Inhibits TS) |
  • | -> Fatal Neutropenic Sepsis, +---> FUTP (Incorporates RNA) |
  • | Diarrhea, Toxic Megacolon +---> FdUTP (Incorporates DNA) |
  • +-----------------------------------------------------------------------------+
  • A. 5-Fluorouracil (5-FU) & Capecitabine

Mechanism: Converted to fluorodeoxyuridine monophosphate ( FdUMP ), which forms a stable ternary covalent complex with Thymidylate Synthase (TS) and 5,10-methylene-THF, inhibiting thymidine synthesis. Also converted to FUTP (incorporated into RNA, inhibiting processing) and FdUTP (incorporated into DNA).

Bolus vs. Continuous Infusion 5-FU Toxicity Profile:

IV Bolus 5-FU: Primarily RNA incorporation → \rightarrow → Dose-Limiting Toxicity (DLT): Myelosuppression (neutropenia, thrombocytopenia) and Mucositis .

Continuous IV Infusion 5-FU (e.g., 46-hr infusion in FOLFOX/FOLFIRI): Prolonged TS inhibition → \rightarrow → DLT: Hand-Foot Syndrome (Palmar-Plantar Erythrodysesthesia [PPE]), Diarrhea, and Coronary Vasospasm / Cardiotoxicity (angina, ischemic ECG changes).

Leucovorin Modulation with 5-FU:

Critical Difference from MTX: In 5-FU regimens, Leucovorin is NOT a rescue agent ; it is a biochemical enhancer . Leucovorin supplies excess 5,10-methylene-THF, which stabilizes the ternary inhibitory complex with TS, dramatically increasing 5-FU cytotoxicity and host toxicity.

Capecitabine (Xeloda): Oral prodrug converted to 5-FU inside tumor cells via a 3-step enzymatic cascade culminating in Thymidine Phosphorylase (TP) .

Dosed with food (within 30 minutes after a meal).

Drug-Drug Interactions: Severe inhibition of CYP2C9 → \rightarrow → massive increase in Warfarin levels/INR with fatal bleeding risk. Switch warfarin to LMWH or DOACs. Aluminum/magnesium antacids increase capecitabine absorption/AUC.

B. DPYD (Dihydropyrimidine Dehydrogenase) Pharmacogenomics

Biology: DPD is the rate-limiting enzyme responsible for > 80 % >80\% > 80% of 5-FU catabolism in the liver.

Genetic Variants: DPYD *2A (c.1905+1G>A), *13 (c.1679T>G), c.2846A>T, and HapB3 (c.1129-5923C>G / c.1236G>A).

Clinical Phenotypes (CPIC Guidelines):

Normal Metabolizer (Activity Score 2.0): Standard 100% dosing.

Intermediate Metabolizer (Activity Score 1.0–1.5): 50% starting dose reduction , titrate in subsequent cycles based on clinical tolerance.

Poor Metabolizer (Activity Score 0–0.5): Complete DPD deficiency. Strongly avoid fluoropyrimidines (5-FU, capecitabine, trifluridine/tipiracil) due to extreme risk of fatal toxic megacolon, pancytopenia, and neurotoxicity.

C. Uridine Triacetate (Vistogard): Fluoropyrimidine Antidote

Indication: FDA-approved specific antidote for 5-FU or capecitabine overdose (regardless of symptoms) or for patients exhibiting early-onset, life-threatening toxicities (severe diarrhea, mucositis, cardiotoxicity, neutropenia) within 96 hours of administration.

Mechanism: Oral prodrug of uridine. Phosphorylated to UTP, which competitively displaces toxic fluorouridine metabolites from RNA incorporation, terminating cellular toxicity.

Dosing: 10 grams orally every 6 hours for 20 doses (children: 6.2 g/m 2 PO q6h 6.2\text{ g/m}^2\text{ PO q6h} 6.2 g/m 2 PO q6h ). Must be initiated within 96 hours of 5-FU/capecitabine completion for maximal survival benefit ( > 95 % >95\% > 95% survival vs. < 15 % <15\% < 15% in historical controls).

D. Cytarabine (Ara-C): Low-Dose vs. High-Dose (HiDAC)

Mechanism: Deoxycytidine analog; phosphorylated to Ara-CTP, which inhibits DNA polymerase- α \alpha α and − β -\beta − β and incorporates into DNA causing chain termination.

High-Dose Cytarabine (HiDAC ≥ 1 , 000 – 3 , 000 mg/m 2 \ge 1,000\text{--}3,000\text{ mg/m}^2 ≥ 1 , 000 – 3 , 000 mg/m 2 in AML):

Cerebellar Neurotoxicity: Manifests as dysmetria, past-pointing, ataxia, dysarthria, nystagmus, and confusion. Caused by Purkinje cell degeneration. Risk factors: Age > 60 years >60\text{ years} > 60 years , renal dysfunction ( Serum Cr ≥ 1.5 – 2.0 mg/dL \text{Serum Cr } \ge 1.5\text{--}2.0\text{ mg/dL} Serum Cr ≥ 1.5 – 2.0 mg/dL ). Mandatory neurological assessments (finger-to-nose, signature/handwriting, gait) prior to EVERY dose. Discontinue HiDAC immediately if ataxia or dysmetria develops (neurotoxicity is irreversible if dosing continues).

Chemical / Hemorrhagic Conjunctivitis: Cytarabine is secreted in high concentrations in tears, causing severe corneal epithelial irritation, photophobia, pain, and blindness. Mandatory Prophylaxis: Corticosteroid ophthalmic drops (Prednisolone acetate 1% or Dexamethasone 0.1% 1–2 drops in both eyes QID) starting 6–12 hours prior to first HiDAC dose and continuing for 48–72 hours after completion.

3. Purine Analogs & Thiopurines (6-MP, 6-TG, Fludarabine, Cladribine) +-----------------------------------------------------------------------------+

  • | 6-MERCAPTOPURINE (6-MP) METABOLIC REGULATION |
  • | |
  • | 6-MERCAPTOPURINE (6-MP) |
  • | | |
  • | +----------------------------+----------------------------+ |
  • | | | | |
  • | v v v |
  • | [Xanthine Oxidase] [TPMT / NUDT15] [HPRT Pathway] |
  • | (Metabolizes to (S-methylation to (Bioactivates to |
  • | inactive 6-thiouric acid) inactive 6-MeMP) active 6-TGN) |
  • | | | | |
  • | x (BLOCKED BY *DEFICIENCY (*2, *3): v |
  • | ALLOPURINOL/ Shunts drug to 6-TGN -> Cytotoxicity |
  • | FEBUXOSTAT) -> Severe Marrow (Marrow |
  • | | Failure Suppression) |
  • | v |
  • | MASSIVE SHUNT TO 6-TGN |
  • | -> FATAL MYELOSUPPRESSION |
  • | *MANDATORY 67-75% DOSE REDUCTION OF 6-MP WITH ALLOPURINOL* |
  • +-----------------------------------------------------------------------------+
  • A. Thiopurine Drug Interactions & Pharmacogenomics

6-MP and Xanthine Oxidase (XO) Inhibitors: Allopurinol and febuxostat block XO-mediated catabolism of 6-MP. When co-prescribed for tumor lysis syndrome or hyperuricemia, the dose of oral 6-MP MUST be reduced by 67% to 75% (administer only 25–33% of standard dose). Note: 6-Thioguanine (6-TG) is deaminated by guanase, not XO, and does not require dose reduction with allopurinol.

TPMT and NUDT15 Pharmacogenomics: Thiopurine S-methyltransferase ( TPMT ) and NUDT15 inactivate thiopurines. Patients homozygous for deficient alleles ( poor metabolizers ) accumulate massive levels of active 6-thioguanine nucleotides (6-TGN), causing fatal bone marrow aplasia. CPIC guidelines require 80–90% dose reductions and reduced dosing frequency in homozygous poor metabolizers.

B. Purine Analogs & Profound Immunosuppression (Fludarabine, Cladribine)

Mechanism: Inhibit ribonucleotide reductase and DNA polymerase, inducing apoptosis in resting and dividing lymphocytes.

Lymphodepletion & CD4+ T-cell Suppression: Produces profound, long-lasting CD4+ and CD8+ lymphopenia persisting for 1 to 2 years.

Supportive Mandates:

PJP Prophylaxis: Bactrim (or dapsone/atovaquone) until CD4+ ≥ 200 cells/ μ L \ge 200\text{ cells/}\mu\text{L} ≥ 200 cells/ μ L .

Antiviral Prophylaxis: Acyclovir or valacyclovir for HSV/VZV reactivation.

Irradiated Blood Products: Transfusion of non-irradiated cellular blood products carries a high risk of fatal Transfusion-Associated Graft-Versus-Host Disease (TA-GVHD) due to donor lymphocyte engraftment in the immunosuppressed host. All blood products must be irradiated for life following purine analog therapy.